Clinical Trials

Carfilzomib (PR-171), our lead proteasome inhibitor, is currently in Phase 1 and Phase 2 clinical trials at leading oncology centers in the United States and Canada. To get additional information on these trials from the ClinicalTrials.gov website operated by the U.S. National Institutes of Health, please click the link below.

Clinical Trial Information about PR-171